Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford AstraZeneca vaccine co-creator Professor Sarah Gilbert collects damehood

General

A scientist who co-created the Oxford/Astrazeneca vaccine has collected her damehood at Windsor Castle. Professor Sarah Gilbert was made a Dame Commander of the British Empire by the Princess Royal today (February 15).

Sarah Gilbert becomes recipient of Sunhak Peace Prize

General

The University of Oxford's Professor Dame Sarah Gilbert has been named a Laureate of the 5th Sunhak Peace Prize for her efforts to protect global health during the COVID-19 pandemic.

Research collaboration launched to focus on repurposing existing anti-viral therapies to treat COVID-19

General

A new £1.6m collaborative project has been launched to rapidly identify new treatments for COVID-19.

Sarah Gilbert elected as RA Honorary Fellow

General

The Royal Academy of Arts has named the University of Oxford's Professor Dame Sarah Gilbert as one of its Honorary Fellows.

£50m funding for Poonawalla Vaccines Research Building at Oxford University

General

The Poonawalla Vaccines Research Building is to be established at Oxford University following £50m funding commitment from Serum Life Sciences.

Volunteers needed for human challenge trial to study immune response to Covid-19

General Research

Oxford researchers are seeking participants for a trial to discover what happens when people who have either already had Covid-19 or who have been vaccinated are exposed to the original strain of virus

The Richard Dimbleby Lecture

General

Professor Dame Sarah Gilbert delivers an account of the development of the Oxford AstraZeneca Covid-19 vaccine, which has now been used in more than 170 countries.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

General Research

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Load More